# Junta clínica — PT-pseudo_fa4a71ae9a34 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_fa4a71ae9a34",
  "pid": "PT-pseudo_fa4a71ae9a34",
  "task": 1,
  "psa": 4.8,
  "age": 65,
  "months": 2,
  "pirads": "5",
  "psad": 0.19,
  "psav": 1.05,
  "psap": 3.6,
  "vol": 25.31,
  "dre": "Nodus",
  "bx": "Positive",
  "cspca": 0.8035576,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 4.8 ng/mL. PI-RADS 5. PSAD 0.19. Prostate volume 25 mL. DRE nodus. csPCa 0.80.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "90 kg",
    "height": "176 cm",
    "bmi": "29.1",
    "bp": "129/75 mmHg",
    "hr": "56 bpm",
    "smoking": "Non-smoker",
    "last_dental": "1 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "01 Feb 2025",
  "enc_ref": "Dr. H. Martens (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Rising prostate-specific antigen (4.8 ng/mL) combined with a confirmed ISUP GG 4 result from a previous biopsy procedure."
    },
    {
      "s": "History",
      "t": "Investigated initially for an incidental prostate-specific antigen elevation in the middle of 2023, this 65-year-old individual subsequently received a positive biopsy result confirming ISUP GG 4 disease. He works as a retired carpenter, resides with his partner, and reports being never married. A non-smoker with no active medications or comorbid conditions, he maintains a regular cycling regimen five days weekly and restricts alcohol to four units per week. Lower urinary tract symptoms remain minimal, reflected by an International Prostate Symptom Score of 3 out of 35, and he explicitly denies hematuria or pelvic discomfort. His clinical background is otherwise unremarkable aside from a recent dermatology visit for actinic keratosis screening. Commuting over an hour by train, he favors flexible scheduling to accommodate his travel routine."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: firm, discrete nodule palpable in the right lobe; mobility: unrestricted; asymmetry: noted only at the nodular site, with the remainder of the gland presenting symmetrically and smooth. Vital parameters demonstrate stability, registering a blood pressure of 129/75 mmHg and a heart rate of 56 bpm. Systemic inspection reveals no palpable lymphadenopathy or abdominal abnormalities."
    }
  ],
  "occupation": "retired carpenter",
  "marital": "Never married",
  "living": "Lives with partner",
  "next_of_kin": "Sibling (sister)",
  "recent_other": [
    "Dermatology — actinic keratosis check"
  ],
  "alcohol": "4 units / week",
  "exercise": "Cycling 5x/week (commuter)",
  "ipss": "IPSS score: 3/35 (mild LUTS)",
  "admin": "Patient travels 60+ min by train to clinic; allow buffer.",
  "mri_hospital": "Catharina Ziekenhuis (Eindhoven)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_fa4a71ae9a34
Task: 1

Encounter: Urology - outpatient on 01 Feb 2025.
Referrer: Dr. H. Martens (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 65-year-old male
  - PSA: 4.8 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.19 ng/mL²
  - PSA velocity: 1.05 ng/mL/yr
  - Prior PSA: 3.6 ng/mL
  - Prostate volume: 25.31 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8035576 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 4.8 ng/mL. PI-RADS 5. PSAD 0.19. Prostate volume 25 mL. DRE nodus. csPCa 0.80.

Vitals: weight 90 kg, height 176 cm, BMI 29.1, BP 129/75 mmHg, HR 56 bpm. Smoking: Non-smoker.

Chief complaint: Rising prostate-specific antigen (4.8 ng/mL) combined with a confirmed ISUP GG 4 result from a previous biopsy procedure.

History: Investigated initially for an incidental prostate-specific antigen elevation in the middle of 2023, this 65-year-old individual subsequently received a positive biopsy result confirming ISUP GG 4 disease. He works as a retired carpenter, resides with his partner, and reports being never married. A non-smoker with no active medications or comorbid conditions, he maintains a regular cycling regimen five days weekly and restricts alcohol to four units per week. Lower urinary tract symptoms remain minimal, reflected by an International Prostate Symptom Score of 3 out of 35, and he explicitly denies hematuria or pelvic discomfort. His clinical background is otherwise unremarkable aside from a recent dermatology visit for actinic keratosis screening. Commuting over an hour by train, he favors flexible scheduling to accommodate his travel routine.

Physical examination: DRE — texture: firm, discrete nodule palpable in the right lobe; mobility: unrestricted; asymmetry: noted only at the nodular site, with the remainder of the gland presenting symmetrically and smooth. Vital parameters demonstrate stability, registering a blood pressure of 129/75 mmHg and a heart rate of 56 bpm. Systemic inspection reveals no palpable lymphadenopathy or abdominal abnormalities.

Patient info: retired carpenter; Never married; Lives with partner.
Next of kin: Sibling (sister).

Lifestyle: alcohol 4 units / week; exercise Cycling 5x/week (commuter); IPSS score: 3/35 (mild LUTS).

Recent other appointments: Dermatology — actinic keratosis check.
Admin: Patient travels 60+ min by train to clinic; allow buffer.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.55
  uncertainty  +/- 0.10 epistemic (95% band 0.35-0.75); among patients I cannot tell apart the outcome was 0.99 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; the levels are what moved my prediction across the series, not what a urologist would mark)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  comorbidity = none recorded (21% of my signal; from pmhx_hypercholesterolaemia, n_comorbidities)
  noted      age = 65 (2% of my signal; from age) · DRE = Nodus (10% of my signal; from dre_suspicious) · PSA = 4.8 ng/mL (3% of my signal; from log_psa, psav) · prostate volume = 25.31 mL (1% of my signal; from log_vol, vol) · PSA density = 0.19 (0% of my signal; from psad_calc, log_psad) · csPCa probability = 0.80 (1% of my signal; from cspca) · PI-RADS = 5 (20% of my signal; from pirads_ge4, pirads_ge3)
  not used   family history
CONFIDENCE: uncertain — 'discuss' tier; out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

I read 39 raw variables, all from the panel — nothing from the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory. Out-of-fold over 91 labelled cases: AUC
0.758, balanced accuracy 0.625.
The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; 'decisive' marks the variable the rule turns on)
  important  prior biopsy = Positive
  noted      age = 65 · DRE = Nodus · PSA = 4.8 ng/mL · prostate volume = 25.31 mL · PSA density = 0.19 · PI-RADS = 5 · comorbidity = none recorded
  not used   family history, csPCa probability
CONFIDENCE: uncertain — none of my three panel rules applies; the fact that would settle it — the documented prior grade — lives in the notes, not on the panel

## Intervención 5 — EXPERT-EXPERIENCE

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

I recall 49 men I have seen in this same situation (Positive prior biopsy). The 3 most similar patients, and what the reading urologist did:
  1. distance 0.61: PI-RADS 5, PSA 6.9, PSAD 0.257, age 67, DRE Nodus -> BIOPSY (uncertain). He wrote: "What was the result of the earlier positive biopsy and the MRI precluding that biopsy? Hard to determine what we are looking at here."
  2. distance 0.71: PI-RADS 5, PSA 6.9, PSAD 0.171, age 67, DRE Nodus -> DEFER (borderline). He wrote: "Need to know if the P5 lesion has grown in size. If not no biopsy."
  3. distance 0.81: PI-RADS 5, PSA 8.3, PSAD 0.215, age 66, DRE Suspicious -> DEFER (clear). He wrote: "This person should discuss curative treatment (younger patient with palpable, MRI-visible high-risk disease incl Gleason 5 findings). If not curative treatment for any r…"

PRECEDENT: DEFER (weighted vote 0.38 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What my professional experience contributes: it shows what this urologist looks at and how he phrases the call. These memories do not establish facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

WHAT THE READING UROLOGIST WEIGHED IN THESE PRECEDENTS — in the form's vocabulary, with this man's values (weighted majority of the 3 nearest labelled traces; the distance itself is on PI-RADS, prior biopsy first)
  important  prior biopsy = Positive · DRE = Nodus · PSA = 4.8 ng/mL · PI-RADS = 5 · comorbidity = none recorded
  noted      family history = not opened (0 of 91) · age = 65 · prostate volume = 25.31 mL · PSA density = 0.19
  not used   csPCa probability
CONFIDENCE: uncertain — in this situation the library is no better than chance (47% out of fold)

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.

WHAT HE WEIGHS — in the form's vocabulary, with this man's values (these are the levels that go on the form, unless a colleague shows a reason to move one)
  important  prior biopsy = Positive · age = 65 · DRE = Nodus · PSA = 4.8 ng/mL · PI-RADS = 5
  noted      family history = not opened (0 of 91) · prostate volume = 25.31 mL · PSA density = 0.19 · comorbidity = none recorded
  not used   csPCa probability
CONFIDENCE: clear — the level the reading urologist records in this situation, from his labelled traces

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The retrieved guidelines discuss using a risk-based pathway based on PI-RADS score, PSA density, and prior biopsy status. The guideline suggests that for patients with a PI-RADS score of 1-3 and a low-risk profile (PSA-D < 0.15ng/mL/cc, negative DRE, no family history, no ASAP or ISUP1 cancer at prior biopsy), biopsy could be avoided in 99 men.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, your bid of BIOPSY p(biopsy) = 0.55 is not settled by the guideline, as the guideline suggests avoiding biopsy in low-risk profiles. The guideline treats the variable csPCa probability as context, whereas the guideline suggests that if the patient fits the low-risk profile, the guideline makes the decision to forgo biopsy. The guideline requires the prior biopsy status to be known, which is a fact already present, but the guideline makes the decision based on the combination of risk factors, not just the prior status. The guideline needs the patient's PSA density to be known, which is a fact already present, but the guideline makes the decision based on the combination of risk factors, not just the prior status.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the prior biopsy status: at Positive the guideline suggests that the decision depends on the documented grade of the prior biopsy and the surveillance history.
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA velocity: the guideline suggests that the PSA velocity is a factor in determining the need for further investigation.
laboratory_results - the PSA density: the guideline makes the decision based on the PSA density threshold of 0.15ng/mL/cc.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

The case hinges on the documented grade of the prior biopsy and the surveillance history, as the guideline suggests this is key when the prior biopsy was positive.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine whether the lesion is compared against an earlier study.
  psa_trend (get_psa_trend) -> Determine the PSA velocity.
  previous_notes (get_previous_notes) -> Determine the documented grade of the prior biopsy and the surveillance history.
  laboratory_results (get_lab_results) -> Determine the PSA density.

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented grade of the prior biopsy?
  Q2. Is the lesion in the radiology_report compared against an earlier study?
  Q3. What is the PSA velocity?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report: Catharina Ziekenhuis, Eindhoven. The lesion is compared against an earlier study: "no comparison made" is not stated, but the report describes the findings of the current scan.
psa_trend: The PSA velocity is rising: "PSA 1.05 ng/mL/yr" is noted, with values from "Jun 2023" (1.2 ng/mL), "Dec 2023" (4.6 ng/mL), "Jul 2024" (3.6 ng/mL), and "Feb 2025" (4.8 ng/mL).
previous_notes: The documented grade of the prior biopsy and the surveillance history: "Positive" biopsy result is noted, and the notes mention a follow-up review on "06 Jun 2024" regarding a trajectory climbing to 3.6 ng/mL, with no specific surveillance protocol mentioned in the retrieved text.
laboratory_results: The PSA density is "0.19 ng/mL/cc" as reported in the MRI report, which is derived from the lab results panel.

WHAT I DID NOT OPEN
family-history anamnesis, because the expert-trace model indicated it was not opened and the decision hinges on the documented prior biopsy grade and surveillance history.

WHAT THIS SUPPORTS
FOR sampling this patient now:
- previous_notes: "Positive" biopsy result is noted, suggesting the need to review the documented grade and surveillance history.
- psa_trend: The PSA velocity of "1.05 ng/mL/yr" indicates a rising trend, which is a factor in determining the need for further investigation per EAU guidelines.
AGAINST sampling this patient now:
- laboratory_results: The PSA density of "0.19 ng/mL/cc" is above the EAU threshold of 0.15 ng/mL/cc, which might suggest a higher risk profile based on guideline context.

WHERE THIS LEANS
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 4.80 ng/mL over 4 points spanning 20 months; velocity +1.71 ng/mL per year; doubling time about 12 months.
PROJECTION at 6 months: 7.2 ng/mL, conformal 95% band 2.1-25.1.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (the serial PSA only)
  noted      PSA = 4.8 ng/mL
  not used   prior biopsy, family history, age, DRE, prostate volume, PSA density, csPCa probability, PI-RADS, comorbidity
CONFIDENCE: borderline — the conformal band does not clear the last value

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.52
  uncertainty  +/- 0.08 epistemic (95% band 0.37-0.67), of which 0.00 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 61% of the time over the 31 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel + the documents that were opened; PI-RADS here means the report's own wording — DWI restriction, lesion size — not the score)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  PI-RADS = 5 (22% of my signal; from rad_dwi_restriction, rad_lesion_ge15mm)
  noted      DRE = Nodus (5% of my signal; from dre_suspicious) · PSA = 4.8 ng/mL (21% of my signal; from fpsa_lt15, psa_delta_prev) · prostate volume = 25.31 mL (4% of my signal; from log_vol, vol) · PSA density = 0.19 (0% of my signal; from psad_calc) · comorbidity = none recorded (4% of my signal; from n_comorbidities, on_alpha_blocker)
  not used   family history, age, csPCa probability
CONFIDENCE: uncertain — 'discuss' tier; out-of-fold it was right 61% of the time over the 31 labelled cases in this tier

Out-of-fold AUC 0.794. I am the only expert that has read the report's
wording, and I still cannot see the prior grade or the surveillance history: those are in the notes, and
the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.55  ('discuss' tier; weight 1.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.52  ('discuss' tier, fusion_full; weight 1.5)
  EXPERT-EXPERIENCE  DEFER, p(biopsy)=0.38  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.53 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('discuss' tier, fusion_full). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.
Dissenting on the board: EXPERT-EXPERIENCE. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

THE BOARD'S VARIABLES — value · what each expert marked · what goes on the form
  bx           Positive                     E1:DEC E3:DEC cohort:IMP library:IMP E2:—            -> important
  fh           not opened (0 of 91)         E1:— E3:— cohort:— library:not E2:—                  -> not_used (raised from noted by the board)
  age          65                           E1:not E3:— cohort:not library:not E2:—              -> important
  dre          Nodus                        E1:not E3:not cohort:not library:IMP E2:—            -> important
  psa          4.8 ng/mL                    E1:not E3:not cohort:not library:IMP E2:not          -> important
  vol          25.31 mL                     E1:not E3:not cohort:not library:not E2:—            -> noted
  psad         0.19                         E1:not E3:not cohort:not library:not E2:—            -> noted
  cspca        0.80                         E1:not E3:— cohort:— library:— E2:—                  -> not_used
  pirads       5                            E1:not E3:IMP cohort:not library:IMP E2:—            -> important
  comorbidity  none recorded                E1:IMP E3:not cohort:not library:IMP E2:—            -> noted
  (DEC decisive · IMP important · not noted · — not used; the last column is the level recorded, from the trace of the reading urologist)

Confidence to record: borderline.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents the registrar opened appear to have addressed the moderator's questions. The `previous_notes` addressed Q1 by noting a "Positive" biopsy result, the `radiology_report` addressed Q2 by stating "no comparison made," and the `psa_trend` addressed Q3 by noting a rising PSA velocity of "1.05 ng/mL/yr."

ALIGNMENT WITH THE PANEL
The retrieved evidence supports the PANEL-PROTOCOL's decision of BIOPSY. Specifically, the `previous_notes` confirming a "Positive" biopsy result, combined with the rising `psa_trend` velocity, aligns with the reasoning that the documented prior grade and trajectory are key when the prior biopsy was positive.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented grade of the prior biopsy? Answered by `previous_notes`: "Positive" biopsy result is noted.
Q2. Is the lesion in the radiology_report compared against an earlier study? Answered by `radiology_report`: "no comparison made".
Q3. What is the PSA velocity? Answered by `psa_trend`: The PSA velocity is "1.05 ng/mL/yr".

WHAT CARRIES WEIGHT, AND WHY
prior biopsy: Positive (decisive) because the panel protocol explicitly states the decision hinges on this, and the registrar confirmed it in the notes.
psa: 4.8 ng/mL (important) because the rising trend (1.05 ng/mL/yr) is noted, which supports the leaning towards biopsy per the registrar's summary.
psad: 0.19 (noted) because it is above the EAU threshold of 0.15 ng/mL/cc, suggesting a higher risk profile according to guideline context.
My confidence in the record as it stands is clear, as all questions posed by the moderator were answered by retrieved documents.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy, leaning firmly on the panel's decision, as the documented positive prior biopsy combined with a rising PSA velocity supports this path.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: borderline)

65y male, PSA 4.8, PI-RADS 5, prior positive biopsy, and rising PSA velocity argues for further tissue sampling. The documented grade of the prior biopsy is not recorded, which is a key missing finding. While the PI-RADS 5 suggests high risk, the lack of prior grade necessitates biopsy to determine management pathway. Further staging and treatment planning are required.

What carried weight: bx=important, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes, laboratory_results
